RAAPID, a Louisville, KY–based AI-powered risk adjustment company, has secured a Series A extension.
Investors
Backed by UPMC Enterprises, joining existing investor M12.
UPMC Enterprises is the innovation and venture capital arm of the University of Pittsburgh Medical Center (UPMC). Based in Pittsburgh, the firm focuses on accelerating the development of transformative healthcare technologies through two primary pillars: digital solutions and translational sciences. It leverages UPMC’s extensive clinical network and real-world data to invest in and incubate startups specializing in AI-driven diagnostics, clinical workflow automation, and precision medicine.
RAAPID Use of Funds
The company will use the funding to accelerate the expansion of its clinical AI platform and support co-development initiatives with healthcare partners.
About RAAPID
RAAPID is a healthcare AI company founded by Chetan Parikh. The company develops a compliance-first clinical AI platform powered by neuro-symbolic AI, designed to improve accuracy, transparency, and auditability in medical coding and Medicare Advantage risk adjustment. Powered by proprietary Neuro-Symbolic AI, it delivers defensible accuracy across retrospective, prospective, and RADV audit workflows. Headquartered in Louisville, Kentucky, RAAPID’s platform serves health plans, ACOs, and health systems and is primarily deployed on Microsoft Azure to ensure data control, scalability, and security.
Funding Details
Company: RAAPID, Inc.
Raised: Undisclosed
Round: Series A Extension
Funding Date: March 2026
Lead Investor: UPMC Enterprises
Additional Investors: M12 (Microsoft’s venture fund)
Company Website: https://www.raapidinc.com/
Software Category: Healthcare AI / Medical Coding / Risk Adjustment
Source: https://www.businesswire.com/news/home/20260318977628/en/